Kornimate/medical-research-clean huggingface dataset:
light emitting diode-red light (led-rl) phototherapy for skin scarring prevention

Conditions: Fibrosis; Skin Scarring; Skin Wound; Hypertrophic Scar; Scar; Keloid

Summary: skin scarring (fibrosis) is a common complication in the wound healing process and remains a therapeutic challenge. scar formation often occurs following injury to the skin such as surgery, trauma, and burns. the goal of this study is to evaluate the safety and efficacy of visible red light as a modality to reduce skin scarring after mini-facelift surgery. based on laboratory data, light emitting diode-red light (led-rl) phototherapy may lessen post-surgical skin fibrosis clinically.

skin fibrosis is a significant global health problem that has a profoundly negative impact on quality of life. characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. in vitro data show that led-rl can modulate key cellular and molecular processes involved in skin fibrosis. two phase i clinical trials (stars 1 and stars 2) demonstrated the safety and tolerability of led-rl at fluences of 160 j/cm2 up to 480 j/cm2 on normal human skin. the administration of led-rl phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. the results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer led-rl as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.

Eligibility criteria:
inclusion criteria: * provision of written informed consent for all study procedures * stated willingness to comply with all study procedures and availability for the duration of the study * suitable candidate for elective mini-facelift surgery * pass a screening photosensitivity test exclusion criteria: * current use of any photosensitizing medications * light-sensitive conditions * diabetes mellitus * systemic lupus erythematosus * current tobacco use * history of bleeding or coagulation disorder * lax skin associated with genetic disorders * open wounds on the face or neck * fibrotic skin disease, pre-existing scar(s), or other skin conditions affecting the periauricular skin * history of surgery or procedure involving or affecting the periauricular skin within the past 6 months (e.g., prior facelift, fillers, laser therapy) * tattoos that cover the proposed treatment sites on the periauricular skin * any other medical condition(s) that could be compromised by exposure to the proposed treatment

Keywords: light emitting diode light emitting diode-red light visible red light skin fibrosis wound healing scarring
study to confirm efficacy and safety of terlipressin in hepatorenal syndrome (hrs) type 1

Conditions: Hepatorenal Syndrome

Summary: this study is to treat adult patients with hepatorenal syndrome (hrs) type 1. out of every three participants, two will receive terlipressin and one will receive placebo. assignments will be made randomly.

the primary objective of this trial is to confirm the efficacy and safety of intravenous terlipressin versus placebo in the treatment of adult subjects with hepatorenal syndrome (hrs) type 1.

Eligibility criteria:
inclusion criteria: * written informed consent by participant or legally authorized representative * cirrhosis and ascites * rapidly progressive worsening in renal function to a serum creatinine (scr) at least 2.25 mg/dl and meeting a trajectory for scr to double over 2 weeks * no sustained improvement in renal function (less than 20% decrease in scr and scr at least 2.25 mg/dl) at least 48 hours after diuretic withdrawal and the beginning of plasma volume expansion with albumin * discontinues midodrine and octreotide before randomization if applicable exclusion criteria: * serum creatinine level greater than 7.0 mg/dl * at least 1 event of large volume paracentesis (lvp) at least 4 l within 2 days of randomization * sepsis and/or uncontrolled bacterial infection * less than 2 days anti-infective therapy for documented or suspected infection * shock * being treatment with or exposure to nephrotoxic agents, nonsteroidal anti-inflammatory drugs, or significant radiographic contrast agents (within the last 4 weeks) * estimated life expectancy of less than 3 days * superimposed acute liver injury due to drugs, dietary supplements, herbal preparations, viral hepatitis, or toxins, with the exception of acute alcoholic hepatitis * proteinuria greater than 500 mg/day * evidence of obstructive uropathy or parenchymal renal disease on ultrasound or other imaging * tubular epithelial casts, heme granular casts, hematuria or microhematuria (greater than 50 red blood cells per high power field in the absence of recent catheterization) on urinalysis * pregnancy; all women of child-bearing age and potential must have a negative pregnancy test * cardiovascular disease judged by the investigator to be severe * current or recent renal replacement therapy (rrt) within the past 4 weeks * participation in other clinical research involving investigational medicinal products within 30 days of randomization * transjugular intrahepatic portosystemic shunt (tips) within 30 days of randomization * use of vasopressors for at least 3 consecutive days within the 14-day screening period - patients receiving any vasopressor other than midodrine and octreotide within 24 hours of qualifying scr are also excluded, ie, a 24-hour washout is required prior to enrollment * known allergy or sensitivity to terlipressin or another component of the study treatment

Keywords: type 1
functional rehabilitation with huber platform in the treatment of non-specific chronic low back pain.

Conditions: Chronic Low-back Pain

Summary: the objective of this study is to evaluate the effectiveness of centre-based program of 6 weeks with huber platform on the spine flexion-to-extension ratio at 60 and 120˚/s, pain and trunk flexibility in individuals with chronic low back pain (clbp). a total of 70 individuals with non-specific chronic low back pain will be randomised into 2 intervention arms (1:1 ratio) that will be blindly evaluated: 1/ standard rehabilitation group and 2/ huber rehabilitation group. both programs are centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week.

the prevalence of chronic low back pain (clbp) is increasing with age and the prevalence of sedentary lifestyle. according to guidelines, non-pharmacological approaches such as exercise and physical therapy have been proposed in first line treatments along with psychological follow-up and pain medication if needed. the physiotherapy, used in a comprehensive clbp rehabilitation program, aims to decrease chronic pain and promotes proprioceptive and postural work, as well as spinal mobility, flexibility and muscle strengthening of the spinal area. isokinetic concentric strength assessment at 60 and 120˚/s is one of the most commonly used criteria to examine the trunk flexors and extensors muscles strength. the objective of this study is therefore to evaluate the effectiveness of an intensive care program with huber platform on the spine flexion-to-extension ratio at 60 and 120˚/s measured by cybex, pain and trunk flexibility in individuals with non-specific clbp. a total of 70 individuals with clbp will be randomised into 2 intervention arms (1:1 ratio) that will be blindly evaluated: 1/ standard rehabilitation group and 2/ huber rehabilitation group. both programs are centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week. all the sessions will be supervised by a physiotherapist and will include 1h of physiotherapy, 30min of balneotherapy and 30min of exercise on cycloergometer for the standard rehabilitation group or 30min of exercise on the huber platform for the huber group. all patients included will benefit from medical monitoring, evaluations and the rehabilitation program set up at the clinique de tréboul, douarnenez, france.

Eligibility criteria:
inclusion criteria: * people aged between 20 - 55 years old * with non-specific chronic low back pain (over 3 months) * with clinical and radiological assessment. exclusion criteria: * chronic low back pain of specific etiology (trauma, tumor, inflammatory or infectious disease, and radicular syndrome) * spine with major anatomical deformations * any contraindication for the rehabilitation program * surgery less than 3 months and/or receiving treatment with corticosteroids.

Keywords: isokinetic physical activity rehabilitation huber platform
predicting fluid responsiveness in on pump coronary artery bypass graft using extra systoles

Conditions: Hypovolemia; Coronary Artery Disease; Fluid Overload

Summary: the purpose of this study is to determine if extra systoles can be used to predict fluid responsiveness perioperatively in patients undergoing on pump coronary artery bypass graft (cabg) surgery. as an additional study we will investigate the ability of a mini fluid challenge to predict response of a larger volume of fluid.

from induction of anaesthesia to cardioplegia we will serve two fluid challenges. before and after each challenge we will collect hemodynamic data and use this to asses our two hypotheses. fluid responsiveness (the outcome to predict) will be defined as a 15% increase in stroke volume(sv) from immediately before fluid infusion is initiated (baseline) to after the full fluid infusion. stroke volume is derived from the gold-standard pulmonary artery catheter measurement of cardiac output(co), which is standard monitoring for these patients (sv = co/heart rate). from subsequent offline analysis of the extracted curve data we will investigate if post-ectopic characteristics from identified extra systoles during the baseline period can predict fluid responsiveness (i.e. the sv change). this analysis addresses the primary hypothesis. also, we will analyse the arterial waveform related to the mini fluid challenge for morphologic changes (comparing heart beats before the infusion with heart beats during the infusion) and see if such transient changes, e.g. in systolic blood pressure, are able to predict fluid responsiveness. this analysis addresses the secondary hypothesis.

Eligibility criteria:
inclusion criteria: * predominant sinus rhythm (no atrial fibrillation, trigemini, 2nd and 3rd degree atrioventricular block also if pacing is present etc.) exclusion criteria: * ejection fraction \< 35% (safety limit minimising risk of fluid overload) * haemodialysis (safety precaution for patients with end-stage kidney failure) * pregnancy * mentally retarded (due to lack of capability to sign an informed consent)

Keywords: fluid responsiveness perioperative extra systoles coronary artery bypass systolic arterial pressure
artesunate ointment for the treatment of high grade vulvar intraepithelial neoplasia (hsil vin2/3)

Conditions: Vulvar Dysplasia; HPV-Related Vulvar Intraepithelial Neoplasia; Preinvasive Vulvar Disease; Vulva Intraepithelial Neoplasia; Vulvar Diseases

Summary: this is a phase i, proof-of-concept treatment study to evaluate the safety, tolerability and feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial neoplasia (hsil vin2/3).

phase i open-label dose escalation study of topical artesunate, formulated as ointment, in the treatment of adult females with biopsy-confirmed hsil vin2/3. fifteen (15) subjects will undergo up to a total of three cycles of topical artesunate. the first cycle will be initiated on day 0, the second at week 2, and the third and final cycle at week 4. primary objective: to evaluate the safety and tolerability of artesunate ointment applied topically on vin2/3 lesions to measure the effect of artesunate ointment on histologic regression of hsil/vin2/3 to vin1 or less, confirmed by a colposcopically-directed biopsy, at study week 15.

Eligibility criteria:
inclusion criteria: * colposcopically-directed biopsy diagnosis of high-grade vulvar dysplasia (vin2, vin3, vin2/3, hsil), including both new and recurrent disease. * females of childbearing potential: negative urine pregnancy test * ability to provide informed consent * ability to collaborate with planned follow-up (transportation, compliance history, etc.) * use of contraception through the study exit visit (week 28) exclusion criteria: * concomitant use of any topical immune modulating agents e.g. imiquimod, aldara ® * cluster of differentiation 4 (cd4) count \< 200 at the time of screening for eligibility. * unable to provide informed consent * currently receiving systemic chemotherapy or radiation therapy for another cancer. * pregnant females * concurrent dermatological disorders involving the vulva (i.e., herpes, ulceration secondary to crohn's disease) or vulvar dermatosis (i.e., lichen planus, lichen sclerosus, or lichen simplex chronicus); * women weighing less than 50 kg

Keywords: artesunate pre-invasive disease treatment alternative non-surgical cancer prevention
pta vs. primary stenting of sfa using self-expandable nitinol stents

Conditions: Peripheral Vascular Diseases; Intermittent Claudication; Angioplasty

Summary: the investigators evaluated whether primary implantation of a self-expanding nitinol stent yielded anatomical and clinical benefits superior to those afforded by percutaneous transluminal angioplasty with optional secondary stenting.


Eligibility criteria:
inclusion criteria: * symptomatic peripheral artery disease with severe intermittent claudication (fontaine stage iib) * critical limb ischemia in patients with stenosis or occlusions originating in the sfa * up to 25 cm length of stenosis/occlusion exclusion criteria: * previous bypass surgery at the site of treatment * history of intolerance of anti-platelet therapy * adverse reaction to heparin * bleeding diathesis * creatinine \>2.5 mg/dl * active bacterial infection * allergy to contrast media * previous stent placement at or immediately adjacent to the target lesion

Keywords: peripheral vascular diseases intermittent claudication angioplasty
an exploratory pharmacogenomic study of monotherapy erbitux in subjects with metastatic non small cell lung carcinoma

Conditions: Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis

Summary: the purpose of this study is to predict responses to erbitux as a single agent in patients with non small cell lung cancer


Eligibility criteria:
inclusion criteria: * measurable disease tumor available for biopsies * life expectancy of at least 3 months exclusion criteria: * known or documented brain metastases prior to cetuximab therapy

Keywords: metastatic non small cell lung cancer
safety and efficacy study of two dose regimens of becocalcidiol in the treatment of plaque-type psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the efficacy and safety of two dosing regimens of qrx-101 ointment (75 mcg/g qd and 75mcg/g bid) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks


Eligibility criteria:
inclusion criteria: * clinical diagnosis of stable plaque-type psoriasis affecting 2% to 10% of the subject's body surface area * psoriasis of a severity that is appropriate for treatment with topical therapy; pga of at least 3 (moderate) at baseline; pss of at least 7, and with no individual symptom score (erythema, induration, or scaling) less than 2 * subject must sign the irb approved informed consent and agree to follow dosing instructions and complete required clinic visits. exclusion criteria: * pregnant or nursing females * systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged sun exposure or ultraviolet light therapy within 4 weeks of dosing * topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other treatment indicated for psoriasis within 2 weeks of dosing * untreated bacterial, tubercular, fungal or any viral lesion of the skin * biologic agents/monoclonal antibodies in the last 6 months * currently using lithium or plaquenil * currently using a beta-blocking medication or thiazide diuretic and the dose has not been stabilized for at least 6 months * history of hypercalcemia or evidence of vitamin d toxicity * current or history of melanoma skin cancer in the past 5 years

Keywords: psoriasis topical therapy
safety and efficacy study of onabotulinumtoxina for the treatment of urinary incontinence due to neurogenic detrusor overactivity (ndo) in non-catheterizing patients with multiple sclerosis (ms)

Conditions: Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder

Summary: this study will evaluate the safety and efficacy of onabotulinumtoxina (botox®) for the treatment of urinary incontinence due to ndo in non-catheterizing patients with ms.


Eligibility criteria:
inclusion criteria: * at least 3 episodes of urinary incontinence over a 3-day period * history of multiple sclerosis (ms) * urinary incontinence not adequately controlled by anticholinergic medication exclusion criteria: * current use of intermittent catheter or indwelling catheter to manage urinary incontinence * previous or current botulinum toxin therapy of any serotype for any urological condition * previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks * diagnosis of myasthenia gravis, eaton-lambert syndrome, or amyotrophic lateral sclerosis
prevalence of secondary hyperparathyroidism among patients with diabetic nephropathy

Conditions: Secondary Hyperparathyroidism; Diabetic Nephropathies

Summary: the aim of this study is to evaluate the prevalence of secondary hyperparathyroidism among patients with diabetic nephropathy.


Eligibility criteria:
inclusion criteria: * \[1\] age was above 18 years, \[2\] patient had diabetic nephropathy which was diagnosed based on the presence of urinary albumin/creatinine ratio (uacr) ≥ 30 mg/gm ± 24 hours' urinary protein measurement ≥ 300 mg/day exclusion criteria: * \[1\] patients were already receiving cinacalcet and/or \[2\] patients had undergone neck surgery for parathyroidectomy.
the anti-fungal effect of miconazol versus miconazol-loaded chitosan nanoparticles

Conditions: Oral Thrush

Summary: objective: this study aimed to evaluate the therapeutic effects of topical application of miconazole and miconazole-loaded chitosan nanoparticles in treatment diabetic patients with oral candidiasis.

abstract: objective: this study aimed to evaluate the therapeutic effects of topical application of miconazole and miconazole-loaded chitosan nanoparticles in treatment diabetic patients with oral candidiasis. subjective and methods: in this randomized controlled clinical trial,. a total of 80 diabetic patients presenting with symptomatic oral candidiasis were randomly assigned into two treatment groups: miconazole and miconazole-loaded chitosan nanoparticles. the patients were treated for a duration 28days , and clinical assessments were conducted at baseline, 7, 14, 21 and 28 days. microbiological analysis was performed to determine the candida species and assess their susceptibility to the antifungal agents. clinical parameters, including signs and symptoms of oral candidiasis, were also evaluated. .

Eligibility criteria:
inclusion criteria: 1. uncontrolled diabetes patients with oral candidiasis and their uncontrolled diabetes were confirmed by doing glycated hemoglobin test and their range is \>7.0%, 2. age ranged from 30-65 years 3. patients were willing to participate in this study exclusion criteria: 1. immunocompromised and patients with systemic diseases that can cause muscle weakness as parkinson's disease, or others that can limit their cognitive functioning such as dementia 2. pregnant 3. nursing women 4. smokers 5. alcoholic patients were also excluded from the study. 6. should not have a history of use of any drugs that can cause hyposalivation or broad spectrum antibiotics, within the last month.

Keywords: diabetic patients or oral candidiasis or oral thrush
conventional versus patient-specific instruments in total knee arthroplasty

Conditions: Osteoarthritis, Patient-specific Instruments

Summary: total knee arthroplasty (tka) has a high success rate for addressing pain and improving function. however, in instances where incorrect positioning and malignment of the tka components are observed, patients can experience a range of negative postoperative outcomes such as loss of thickness of polyethylene tibial bearings, eccentric loading, implant loosening, and eventual early revision. to avoid these complications, achieving a postoperative alignment within the range of 0°±3° of the mechanical axis is recommended. manual intramedullary/extramedullary guides are not thought to be capable of consistently achieving axes in this range, and though computer-assisted navigation has shown superior results in comparison with conventional instrumentation, it is also limited by increased surgical times and no clear superiority in improving short-term clinical outcomes. thus, there has been in a push in the orthopaedic community to create more precise technologies to aid in the reconstruction of the knee's mechanical axis. patient-specific instrumentation (psi), which uses anatomical data obtained primarily from pre-operative axial computed tomography (ct) or magnetic resonance imaging (mri) to create disposable cutting jigs individualized to the patient's unique anatomy, was created with this goal. this study aims to compare the clinical results of conventional and patient-specific instruments in total knee arthroplasty.

the objective of this work was to compare pain, stiffness, function and accuracy between groups at minimum 2 year postoperatively. the investigators hypothesized that psi would lead to a neutral mechanical axis on average more frequently than conventional instrumentation. the study design is a double-blind randomized controlled trial. randomly, fifty patients planed to undergo total knee arthroplasty using conventional instruments and other fifty patients undergo total knee arthroplasty using patient-specific instruments. the clinical outcome is comparative preoperative, postoperative 6weeks, 3months, 6months and 1years. and clinical score consists of range of motion (rom), womac (western ontario and mcmaster university arthritis index) pain scale (preoperative and postoperative 6, 12, 24 months), knee society score (preoperative and postoperative 6, 12, 24 months), anterior and posterior stress view on x-ray (preoperative and postoperative 6, 12, 24 months).

Eligibility criteria:
inclusion criteria: * over 19 year old * patients for total knee arthroplasty of both knee * over 5 degree in lateral bowing of femur * having medicare insurance exclusion criteria: * rheumatoid arthritis * other inflammatory arthritis * neuropsychiatric patients * hepatic insufficiency * renal insufficiency * over 40 of body mass index * chronic opioid use (taking opioids for longer than 3 months)